Cartalax calculator
A short cartilage-targeted 'peptide bioregulator' marketed for joint support. Evidence is thin and largely regional.
Also known as: Cartilage peptide bioregulator, Ala-Glu-Asp tripeptide
FDA status — not an approved drug Not FDA-approved for any use. Cartalax is a peptide bioregulator sold as a research or supplement product and is not reviewed by FDA.
Schedule Cartalax → Set your dosing schedule and get a phone notification when each dose is due. Free.
What Cartalax is
Cartalax is a short peptide marketed as a cartilage 'bioregulator,' part of the cytomedin class developed in Russia. It is claimed to support joint and cartilage health by normalizing chondrocyte function. It is not approved in the United States and lacks rigorous clinical evidence.
Research depth: 1/5 Limited regional research; no large randomized or Western trials. Human trials: None published in major journals. This measures how much has been studied — counting animal and laboratory work — not whether it works for you.
How Cartalax works
The proposed mechanism, common to this peptide class, is that short peptides penetrate cells and regulate gene expression in a tissue-specific manner to restore normal function. For Cartalax the target is cartilage. This remains a claim without strong independent, controlled validation.
Cartalax side effects
Commonly reported
- Generally reported as well tolerated in regional literature
- No robust Western safety data
Serious — seek medical care
- Evidence base is thin and not independently replicated
- Quality and purity vary widely among suppliers
- Not a substitute for evidence-based joint care
This list is not exhaustive. Report anything unexpected to the clinician who prescribed it. If you have severe abdominal pain, trouble breathing, or signs of an allergic reaction, seek care the same day. See also our guide to peptide side effects by class.
A worked example
A 20 mg vial reconstituted with 1 mL of bacteriostatic water gives 20 mg/mL. A 20000 mcg dose is then 1 mL — about 100 units on a 100-unit insulin syringe, giving roughly 1 doses per vial before accounting for residual volume left in the vial and syringe.
Prefer paper? Download the printable Cartalax dosing chart (PDF) — every vial size and water volume in syringe units, with the same review byline as this page. All charts →
Commonly cited dose range
Figures circulating for Cartalax run from 10000 mcg to 30000 mcg. Bioregulator peptides are typically sold as oral capsules dosed in milligrams. Figures shown are community reference amounts in micrograms. There is no established or approved dose.
Read this as reference information, not instruction. These numbers describe what is commonly discussed, not what is right for any individual. Dose, frequency, and whether to use Cartalax at all are decisions for a licensed clinician who knows your history.
Common questions
Is Cartalax proven to help joints?
No robust, independently replicated clinical evidence supports it. It is a regional bioregulator product with limited data.
How is Cartalax supposed to work?
Like other cytomedin bioregulators, it is claimed to normalize cartilage cell function. This mechanism is not established by rigorous Western research.